Cargando…

Outcomes of a 1-day nonmyeloablative salvage regimen for patients with primary graft failure after allogeneic hematopoietic cell transplantation

Primary graft failure after allogeneic hematopoietic cell transplantation is a life-threatening complication. A shortened conditioning regimen may reduce the risk of infection and increase the chance of survival. Here, we report the outcome of 11 patients with hematologic diseases (median age, 44; r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kanda, Junya, Horwitz, Mitchell E., Long, Gwynn D., Gasparetto, Cristina, Sullivan, Keith M., Chute, John P., Morris, Ashley, Hennig, Therese, Li, Zhiguo, Chao, Nelson J., Rizzieri, David A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3214602/ https://www.ncbi.nlm.nih.gov/pubmed/21804612 http://dx.doi.org/10.1038/bmt.2011.158

Ejemplares similares

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery
por: Green, Michael M. B., et al.
Publicado: (2016)

Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant
por: Pabon, Cindy M., et al.
Publicado: (2021)

What Role Is There for Antithymocyte Globulin in Allogeneic Nonmyeloablative Canine Hematopoietic Cell Transplantation?
por: Diaconescu, Razvan, et al.
Publicado: (2005)

Cognitive impairment in candidates for allogeneic hematopoietic stem cell transplantation
por: Smith, Patrick J., et al.
Publicado: (2022)

Graft-vs-tumor effect in patients with advanced nasopharyngeal cancer treated with nonmyeloablative allogeneic PBSC transplantation
por: Toh, H C, et al.
Publicado: (2011)

Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation
por: Walter, Roland B., et al.
Publicado: (2014)

Nonmyeloablative Allogeneic Stem-Cell Transplantation for Metastatic Renal Cell Cancer: A Review and Update
por: Erotocritou, P., et al.
Publicado: (2006)

(GT)(n) Repeat Polymorphism in Heme Oxygenase-1 (HO-1) Correlates with Clinical Outcome after Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation
por: Køllgaard, Tania, et al.
Publicado: (2016)

Anti-thymocyte globulin with CsA and MMF as GVHD prophylaxis in nonmyeloablative HLA-mismatched allogeneic HCT
por: van der Velden, Walter J. F. M., et al.
Publicado: (2021)

High fludarabine exposure and relationship with treatment-related mortality after nonmyeloablative hematopoietic cell transplantation
por: Long-Boyle, Janel R, et al.
Publicado: (2010)

Graft-versus-Leukemia Effect of Nonmyeloablative Stem Cell Transplantation
por: Imamura, Masahiro, et al.
Publicado: (2009)

Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer
por: Banna, G L, et al.
Publicado: (2006)

A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant
por: Ramalingam, Sendhilnathan, et al.
Publicado: (2021)

Incidence and Pattern of Graft-versus-Host Disease in Patients Undergoing Allogeneic Transplantation after Nonmyeloablative Conditioning with Total Lymphoid Irradiation and Antithymocyte Globulin
por: Veltri, Lauren, et al.
Publicado: (2013)

Kinetics of IL-7 and IL-15 Levels after Allogeneic Peripheral Blood Stem Cell Transplantation following Nonmyeloablative Conditioning
por: De Bock, Muriel, et al.
Publicado: (2013)

Allogeneic bone marrow transplantation can suppress established and otherwise chronic collagen-induced arthritis after a nonmyeloablative conditioning regimen employing anti-CD40 ligand monoclonal antibody
por: Flierman, R, et al.
Publicado: (2004)

Association between the choice of the conditioning regimen and outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis
por: Murthy, Guru Subramanian Guru, et al.
Publicado: (2023)

High prevalence of potential drug interactions affecting mycophenolic acid pharmacokinetics in nonmyeloablative hematopoietic stem cell transplant recipients
por: Jaklič, Alenka, et al.
Publicado: (2013)

Fludarabine and cyclophosphamide provides a nonmyeloablative alternative conditioning regimen with low transplant-related mortality and control of high risk disease
por: Paplham, Pamela, et al.
Publicado: (2014)

Salvaged allogeneic hematopoietic stem cell transplantation for pediatric chemotherapy refractory acute leukemia
por: Wang, Jingbo, et al.
Publicado: (2017)

Autologous nonmyeloablative hematopoietic stem cell transplantion in newly diagnosed childhood type 1 diabetes mellitus: the first year report
por: Luo, Feihong, et al.
Publicado: (2013)

Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial
por: Sung, Anthony D., et al.
Publicado: (2016)

Dipeptidyl peptidase IV (DPPIV/CD26) inhibition does not improve engraftment of unfractionated syngeneic or allogeneic bone marrow after nonmyeloablative conditioning
por: Schwaiger, Elisabeth, et al.
Publicado: (2012)

Salvage use of venetoclax-based therapy for relapsed AML post allogeneic hematopoietic cell transplantation
por: Joshi, Maansi, et al.
Publicado: (2021)

The Use of Allogeneic Hematopoietic Stem Cell Transplantation in Primary Myelofibrosis
por: Wolfe, Heather R., et al.
Publicado: (2022)

Outcomes of Salvage Autologous Versus Allogeneic Hematopoietic Cell Transplantation for Relapsed Multiple Myeloma After Initial Autologous Hematopoietic Cell Transplantation
por: Wirk, Baldeep, et al.
Publicado: (2013)

The association of conditioning regimen with cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation
por: Mardani, Masoud, et al.
Publicado: (2020)

Immune Reconstitution Kinetics following Intentionally Induced Mixed Chimerism by Nonmyeloablative Transplantation
por: Kim, Nayoun, et al.
Publicado: (2015)

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
por: Sivaraj, Dharshan, et al.
Publicado: (2018)

Microvascular Complications in Type 1 Diabetes: A Comparative Analysis of Patients Treated with Autologous Nonmyeloablative Hematopoietic Stem-Cell Transplantation and Conventional Medical Therapy
por: Penaforte-Saboia, Jaquellyne G., et al.
Publicado: (2017)

The salvage role of allogeneic hematopoietic stem-cell transplantation in relapsed/refractory diffuse large B cell lymphoma
por: Min, Gi-June, et al.
Publicado: (2023)

Safety and efficacy of a nonmyeloablative pretransplant conditioning regimen using total lymphoid irradiation with volumetric modulated arc therapy in healthy dogs: A pilot study
por: Kim, Sangho, et al.
Publicado: (2021)

Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide
por: Munchel, Ashley, et al.
Publicado: (2011)

A nonmyeloablative chimeric mouse model accurately defines microglia and macrophage contribution in glioma
por: Yu, K., et al.
Publicado: (2018)

Phase-2 Trial of an Intensified Conditioning Regimen for Allogeneic Hematopoietic Cell Transplant for Poor-Risk Leukemia
por: Stein, Anthony S., et al.
Publicado: (2010)

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML
por: Cao, Xing-yu, et al.
Publicado: (2023)

Deletion of Y chromosome before allogeneic hematopoietic stem cell transplantation in male recipients with female donors
por: Tamaki, Masaharu, et al.
Publicado: (2022)

A convolutional neural network-based model that predicts acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation
por: Jo, Tomoyasu, et al.
Publicado: (2023)

Optimizing allogeneic grafts in hematopoietic stem cell transplantation
por: Xu, Zheng‐Li, et al.
Publicado: (2021)

Disrupted tongue microbiota and detection of nonindigenous bacteria on the day of allogeneic hematopoietic stem cell transplantation
por: Oku, Saori, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_e7kimbr8gtb6cmv20ofqfqf0jv